VISCHER advises GlycoEra on Series A Financing Round
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS) to further support the development of its innovative platform to enable high-throughput design and production of drug development candidates for fast and deep degradation of pathogenic proteins. VISCHER advised GlycoEra on all legal issues related to the transaction.
The VISCHER team included (pictured from left to right) Matthias Staehelin Partner, Corporate/M&A, Pauline Pfirter, Senior Associate, Corporate/M&A and Timothy Woodtli Associate, Corporate/M&A.
